Blue phosphorescent OLED: an analysis of 8 patents

The patent claiming the principle of blue phosphorescence expired in 2020-08. Six years past expiry, no adoption into mass production has been announced. In this stretch where nobody can block it and nobody can build it, we checked against granted patent originals where the actual line of defense has moved.

This article was published before the English edition began, so the labels inside its figures and simulators are in Korean. The caption and the note under each figure are in English.

A patent lasts 20 years. The premise of the system is that you commercialize the technology within that time and recover its value.

Blue phosphorescent OLED is a case where that premise broke. The patent claiming the principle secured priority in 2000-08 and its term ended on 2020-08-11. 6 years on, as of 2026-08, no panel maker has announced putting this technology into mass production.

Nobody now monopolizes that principle. And still nobody can build the product. In this stretch we check against granted patent originals where the actual line of defense has moved.

1. Overview

1.1 Background and purpose

Red and green in OLED crossed from fluorescence to phosphorescence in the 2000s. Phosphorescence uses an internal quantum efficiency of 100% in theory where fluorescence stops at 25%, so the switch translates directly into a power gain. Blue alone is still fluorescent.

The purpose is confirmation, not prediction. We do not guess “when it will come.” We carry over what companies and universities actually wrote in patent specifications and what state those rights are in now.

1.2 Scope

The subject is eight patents spanning 22 years, by priority date from 1997 to 2019. The applicants are Princeton University, the University of Southern California (USC), Universal Display, Kyushu University and Kyulux. In-house material patents from panel makers (Samsung Display, LG Display) were not put into this sample. The lineage of rights in this technology started with material companies and universities.

1.3 Data sources and search

1.4 Classification

The collected patents were classified on two axes: “what produces the blue (the lever)” and “what was given up (the price).” The levers fall into three branches: phosphorescence (use the triplet directly), hybrid (leave only blue fluorescent), and delayed fluorescence (lift the triplet back up to the singlet).

2. Quantitative sketch

2.1 Term roadmap

The two originals have already expired. Only the detour, the 3rd path, and the applications newly filed in 2025 stretch to the right of the present.

2.2 Three numbers

2.3 Lever × price matrix

3. Qualitative analysis: 5 patents

Universal Display US9070884B2 in force

Title

Hybrid OLED having phosphorescent and fluorescent emitters

Bibliography

Priority 2005-04-13 · granted 2015-06-30 · expiry expected 2029-10-16 · status Active

Abstract

An organic light emitting device having combined emission from at least two emissive materials, a fluorescent blue emissive material and a phosphorescent emissive material. It provides a device structure optimizing efficiency and lifetime through a combination of fluorescent and phosphorescent emitters.

Reading

The name of this patent is itself a record of the detour. Since blue cannot be made phosphorescent, leave blue fluorescent and use phosphorescence for red and green only. It was filed in 2005, 5 years after the blue phosphorescence principle patent appeared.

The drawing shows that compromise exactly.

FIG. 3 (US9070884B2): device stack cross section. From the bottom: ITO (anode) · Ir(Ph-ppy)₃ · NPD · CBP:Ir(Ph-ppy)₃ (green phosphorescent) · CBP:Ir(pq)₂(acac) (red phosphorescent) · ADN:BFD47 (blue fluorescent) · Alq₃ · LiF · Al (cathode). Red and green alone use iridium complexes (phosphorescent) while blue alone uses a fluorescent dopant. Original drawing.

The red and green layers have iridium complexes doped into a CBP host. Phosphorescent. Only the blue layer has BFD47 in an ADN host. Fluorescent. Inside one device, blue alone emits by a different principle.

This patent is in force until 2029-10. And as will be seen later, the prototype disclosed in 2026 still uses this structure.

4. Comparative analysis

4.1 A threshold not crossed in a full 20 years

The patent system gives 20 years. Blue phosphorescence used all 20 and did not reach commercialization.

What blocked it has been stated by the rights holder itself. On its technology blog in 2026-06, Universal Display set out that historically a trade-off has repeated in which raising the efficiency or color purity of blue phosphorescence cuts lifetime, and securing lifetime cuts efficiency. The physical reason given is that blue photons carry high energy so the load on the material is large, and producing a deep blue requires pushing current density higher.

Here is where it divides. It was not patents blocking it. The principle was published in 2000 and even the rights were released in 2020, yet the threshold nobody crossed in more than 20 years was the lifetime of the material.

4.2 The detour is still in service after 20 years

The hybrid patent of 2005 looks like a stopgap. A structure to hold out until blue phosphorescence works.

Yet according to the explanation given at Universal Display’s Q2 results on 2026-07-30, the tablet-sized prototypes LG Display disclosed at SID Display Week in 2025 and 2026 were a hybrid tandem structure with blue phosphorescence put into it.

It is not a full conversion. Even with blue phosphorescence inside, the device is still a hybrid. The structure drawn as a detour in 2005 remains the skeleton of the 2026 prototype, and that patent is in force until 2029. The detour became the main line.

4.3 It does not name a date

At the same results call, management was asked repeatedly about the timing of commercialization. President Steven Abramson’s answer was that no specific schedule can be given at this point and that it depends on customers’ commercialization roadmaps.

At the same event the company adjusted its 2026 annual revenue guidance to the lower end of the 630 million to 670 million dollar range. No separate revenue outlook for blue phosphorescence was given.

The fact that the patent has expired and the fact that a date cannot be pinned point the same way. The bottleneck of this technology is not rights but performance.

4.4 The line of defense moved

That the original was released does not make this area unclaimed ground.

Anyone can use the principle. The specific compounds and combinations that actually give usable lifetime are covered by improvement patents with priority dates after 2014. That is why reading the expiry of the original patent as a signal to enter is a mistake. The door opened, but the passage was cut somewhere else.

5. Counter-evidence and limits

• Expiry is not the same as freedom. What expired is the scope claimed by US6939624B2, and subsequent granted patents and pending applications remain in the same technical area. This analysis does not judge freedom to operate.
• CLAIM does not judge infringement or invalidity. The expiry dates and statuses above are a transfer of Google Patents bibliographic data, not a judgment of legal validity.
• Expiry dates are bibliographic values. “Anticipated/Adjusted expiration” is an estimate reflecting term adjustment and may not reflect early lapse from unpaid fees. The register was not obtained.
• Expiry for pending applications is a calculated value. The dotted bars in Figure 1 are the priority date plus 20 years, which may change with term adjustment on grant.
• The scope of material patents is not fully read this way. Compound claims list substituents broadly in Markush form, so the actual coverage is hard to gauge from claim language alone.
• The sample is 8 patents. In-house material patents from panel makers and patents from material companies such as Idemitsu Kosan and Merck were not put in this scope. That is a task for a later piece.
• Mass production is judged by announcement. “No adoption into mass production has been announced” is a statement based on published results calls and materials, not a statement excluding undisclosed production.

6. Conclusions and implications

Three things remain.

First, read the expiry of the original patent as an opportunity, but check the passage again. The principle conditions of blue phosphorescence have been in the public domain since 2020. But the compound compositions that actually give lifetime are covered by patents with priority dates after 2014, and that protection runs to 2034 through 2039. Anyone reviewing material sourcing should look at that band, not the expired original.

Second, hybrid has hardened from a transitional stage into a design standard. The structure of the 2005 detour patent is in the 2026 prototype as it stands, and the right is alive until 2029. A plan that assumes blue phosphorescence arrives as a “full conversion” may not match the actual device structure.

Third, this is a case where timing cannot be predicted from patents. CLAIM reads roadmaps from granted patents, but what the patents told us here was not a schedule but the absence of one. There are technologies that do not work even after 20 years, and at that point a patent tells you not when it will work but what is blocking it. The bottleneck of blue phosphorescence is not rights but lifetime.

Rights on the delayed fluorescence branch remain until 2033. Whether blue goes phosphorescent or delayed fluorescent, or holds out longer as hybrid, is something no patent answers yet.

7. Appendix: full patent specification table

The assignee column is a value confirmed for every patent by opening the Google Patents Application filed by or Current Assignee field directly.